tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

BPH Global Secures Exclusive Rights to Evaluate Ginseng-Based Formulation

Story Highlights
BPH Global Secures Exclusive Rights to Evaluate Ginseng-Based Formulation

Meet Your ETF AI Analyst

Stemcell United Ltd. ( (AU:BP8) ) has provided an announcement.

BPH Global Ltd, a company with a focus on Traditional Chinese Medicine-based natural formulations, has entered into an Exclusive Dealing Agreement with Denmark-based scientist Jo-an Refugio to evaluate a proprietary ginseng-based formulation aimed at enhancing male vitality and wellbeing. This agreement grants BPH Global a six-month exclusivity period to conduct due diligence and product testing, with the potential to acquire intellectual property rights and engage Jo-an as an R&D consultant. The formulation is part of BPH Global’s broader R&D initiative, exploring both natural over-the-counter products and evidence-based, clinically tested products.

More about Stemcell United Ltd.

Current Market Cap: A$2.6M

Learn more about BP8 stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1